Updating results

1961 results

Sort: Relevance | Date

Sleep disordered breathing

Proposed [GID-QS10096] Expected publication date: TBC

Quality standard Proposed

Heart valve disease in adults

Proposed [GID-QS10101] Expected publication date: TBC

Quality standard Proposed

Perioperative care

Proposed [GID-QS10094] Expected publication date: TBC

Quality standard Proposed

Primary hyperparathyroidism

Proposed [GID-QS10089] Expected publication date: TBC

Quality standard Proposed

Thyroid disease

Proposed [GID-QS10088] Expected publication date: TBC

Quality standard Proposed

Parenteral nutrition in neonates

Proposed [GID-QS10087] Expected publication date: TBC

Quality standard Proposed

Diverticular disease

Proposed [GID-QS10086] Expected publication date: TBC

Quality standard Proposed

Pancreatitis (including acute pancreatitis)

Proposed [GID-QS10085] Expected publication date: TBC

Quality standard Proposed

Pain management (young people and adults)

Proposed [GID-QS10093] Expected publication date: TBC

Quality standard Proposed

Primary and secondary brain cancers

Proposed [GID-QS10092] Expected publication date: TBC

Quality standard Proposed

Tinnitus

Proposed [GID-QS10091] Expected publication date: TBC

Quality standard Proposed

Ixekizumab for treating axial spondyloarthritis after NSAIDs [ID1532]

Proposed [GID-TA10458] Expected publication date: TBC

Technology appraisal guidance Proposed

Secukinumab for treating non-radiographic axial spondyloarthritis [ID1419]

Proposed [GID-TA10457] Expected publication date: TBC

Technology appraisal guidance Proposed

Brolucizumab for treating wet age-related macular degeneration [ID1254]

Proposed [GID-TA10455] Expected publication date: TBC

Technology appraisal guidance Proposed

Galcanezumab for preventing migraine [ID1372]

Proposed [GID-TA10454] Expected publication date: TBC

Technology appraisal guidance Proposed

Treosulfan with fludarabine for non-malignant disease before allogeneic stem cell transplant [ID1540]

Proposed [GID-TA10453] Expected publication date: TBC

Technology appraisal guidance Proposed

Dupilumab for treating chronic rhinosinusitis with nasal polyps ID1179

Proposed [GID-TA10450] Expected publication date: TBC

Technology appraisal guidance Proposed

Autologous haematopoietic stem cell transplantation for treating multiple sclerosis (ID1111)

Proposed [GID-TA10306] Expected publication date: TBC

Technology appraisal guidance Proposed

Fingolimod for treating relapsing multiple sclerosis in children and young people [ID1378]

Proposed [GID-TA10336] Expected publication date: TBC

Technology appraisal guidance Proposed

Rituximab for maintenance treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis [ID1320]

Proposed [GID-TA10332] Expected publication date: TBC

Technology appraisal guidance Proposed

Ozanimod for treating relapsing multiple sclerosis [ID1294]

Proposed [GID-TA10299] Expected publication date: TBC

Technology appraisal guidance Proposed

Intravenous zanamivir for treating influenza in hospital [ID1196]

Proposed [GID-TA10298] Expected publication date: TBC

Technology appraisal guidance Proposed

Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing elective surgery [ID1149]

Proposed [GID-TA10297] Expected publication date: TBC

Technology appraisal guidance Proposed

Rivaroxaban for treating chronic heart failure [ID1462]

Proposed [GID-TA10393] Expected publication date: TBC

Technology appraisal guidance Proposed

Lenadogene nolparvovec for treating Leber's hereditary optic neuropathy [ID1410]

Proposed [GID-TA10391] Expected publication date: TBC

Technology appraisal guidance Proposed

Lumacaftor with ivacaftor for treating cystic fibrosis in children aged 2 to 11 years old homozygous for the F508del mutation [ID1486]

Proposed [GID-TA10390] Expected publication date: TBC

Technology appraisal guidance Proposed

Upadacitinib for treating moderate to severe rheumatoid arthritis [ID1400]

Proposed [GID-TA10389] Expected publication date: 18 March 2020

Technology appraisal guidance Proposed

Pitolisant hydrochloride for treating obstructive sleep apnoea ID1065

Proposed [GID-TA10385] Expected publication date: TBC

Technology appraisal guidance Proposed

Ravulizumab for treating paroxysmal nocturnal haemoglobinuria ID1457

Proposed [GID-HST10023] Expected publication date: TBC

Highly specialised technologies guidance Proposed

Prevention and non-surgical treatment of pelvic floor failure/incompetence/prolapse

Proposed [GID-QS10129] Expected publication date: TBC

Quality standard Proposed

Crizanlizumab for preventing sickle cell crises in sickle cell disease [ID1406]

Proposed [GID-TA10470] Expected publication date: TBC

Technology appraisal guidance Proposed

Eculizumab for treating relapsing neuromyelitis optica [ID1271]

Proposed [GID-TA10469] Expected publication date: TBC

Technology appraisal guidance Proposed

STG320 for treating persistent allergic rhinitis caused by house dust mites (ID1278)

Proposed [GID-TA10279] Expected publication date: TBC

Technology appraisal guidance Proposed

Mepolizumab for treating chronic obstructive pulmonary disease (ID1237)

Proposed [GID-TA10239] Expected publication date: TBC

Technology appraisal guidance Proposed

Avacopan for treating anti-neutrophil cytoplasmic antibody-associated vasculitis ID1178

Proposed [GID-TA10199] Expected publication date: TBC

Technology appraisal guidance Proposed

Dexamethasone intracanalicular insert for treating inflammation and pain after cataract surgery ID1154

Proposed [GID-TA10198] Expected publication date: TBC

Technology appraisal guidance Proposed

Adrenal dysfunction

Proposed [GID-QS10038] Expected publication date: TBC

Quality standard Proposed

Acne

Proposed [GID-QS10036] Expected publication date: TBC

Quality standard Proposed

Abdominal aortic aneurysm

Proposed [GID-QS10035] Expected publication date: TBC

Quality standard Proposed

Olaparib with bevacizumab for maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer [ID1652]

Proposed [GID-TA10526] Expected publication date: TBC

Technology appraisal guidance Proposed

Solriamfetol for treating excessive waketime sleepiness caused by narcolepsy [ID1602]

Proposed [GID-TA10524] Expected publication date: 26 June 2020

Technology appraisal guidance Proposed

Fostamatinib for treating persistent or chronic immune thrombocytopenia [ID1087]

Proposed [GID-TA10387] Expected publication date: TBC

Technology appraisal guidance Proposed

Inebilizumab for treating neuromyelitis optica spectrum disorders [ID1529]

Proposed [GID-TA10522] Expected publication date: TBC

Technology appraisal guidance Proposed

Tafamidis for treating transthyretin amyloid cardiomyopathy [ID1531]

Proposed [GID-TA10451] Expected publication date: 10 June 2020

Technology appraisal guidance Proposed

Esketamine for treating major depressive disorder in adults at imminent risk for suicide ID1604

Proposed [GID-TA10518] Expected publication date: TBC

Technology appraisal guidance Proposed

Emapalumab for treating primary haemophagocytic lymphohistiocytosis (ID1438)

Proposed [GID-TA10527] Expected publication date: TBC

Technology appraisal guidance Proposed

Nintedanib for treating progressive fibrosing interstitial lung disease [ID1599]

Proposed [GID-TA10520] Expected publication date: TBC

Technology appraisal guidance Proposed

Ranibizumab for treating diabetic retinopathy [ID1592]

Proposed [GID-TA10521] Expected publication date: TBC

Technology appraisal guidance Proposed